Clinical Research Directory
Browse clinical research sites, groups, and studies.
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
Sponsor: University of Minnesota
Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Official title: CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-10-02
Completion Date
2027-08
Last Updated
2025-10-31
Healthy Volunteers
No
Conditions
Interventions
Cytogam
Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
Locations (1)
University of Minnesota
Minneapolis, Minnesota, United States